Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: June 23, 2004
Last updated: May 10, 2013
Last verified: May 2013

The purpose of this study is to evaluate whether weight-based or fixed starting doses result in comparable hemoglobin increases and treatment effects in patients with heart failure and anemia.

Condition Intervention Phase
Congestive Heart Failure
Drug: Darbepoetin Alfa
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Effects of Treatment With 2 Regimens of Subcutaneous Darbepoetin Alfa (Weight-based Dosing and Fixed Dosing) on Hemoglobin Concentration Response in Subjects With Symptomatic CHF and Anaemia

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Rate of rise of hemoglobin concentration

Secondary Outcome Measures:
  • Change in left ventricular ejection fraction
  • Change in 6-minute walk distance
  • NYHA classification
  • Patient-reported outcomes

Estimated Enrollment: 150
Study Start Date: June 2004

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria: - Symptomatic CHF for at least 3 months - Reduced left ventricular ejection fraction - Stable heart failure medication - Hemoglobin concentration between 9.0 and 12.5 g/dL Exclusion Criteria: - Hypertension - Unstable angina pectoris or recent myocardial infarction - Likely to receive cardiac transplant - Major organ transplant (e.g., lung, liver, heart) or in renal replacement therapy (e.g., dialysis) - Recent or current treatment for malignancy - Systemic hematologic disease - Anemia due to acute or chronic bleeding - Recent Epogen® or darbepoetin alfa therapy - Recent blood transfusion

  Contacts and Locations
Please refer to this study by its identifier: NCT00086086

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT00086086     History of Changes
Other Study ID Numbers: 20020171
Study First Received: June 23, 2004
Last Updated: May 10, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Amgen:
Symptomatic Congestive Heart Failure

Additional relevant MeSH terms:
Heart Failure
Hematologic Diseases
Heart Diseases
Cardiovascular Diseases
Darbepoetin alfa
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 16, 2014